Dr. Gill is the previous chairman of the Department of Urology at the Cleveland Clinic. He is a renowned innovator in the field of minimally invasive urologic surgery and the most experienced laparoscopic/robotic surgeon in the U.S., with his team's experience now approximating 4,000 U.S. cases to date. Dr. Gill was also awarded the St. Paul's Medal by the British Urological Association (BAUS), the highest honor bestowed by the organization.

In addition to his clinical expertise, Dr. Gill is a distinguished researcher in novel robotic devices and image-guidance systems, augmented reality imaging, and innovative focal ablation therapies for prostate and kidney cancer. His team is developing and refining natural orifice and single-port laparoscopic surgery in urology, both innovative concepts towards scar-free surgery.

A prolific scholar, Dr. Gill has authored or co-authored more than 380 peer-reviewed scientific papers, 50 book chapters, and eight textbooks. He is on the editorial board of nine urologic journals and has been a visiting professor at more than 250 institutions and societies worldwide. He has performed live surgery demonstrations at more than 55 centers and was elected to the prestigious American Association of Genito-Urinary Surgeons in 2003.

Marc Oczachowski, Chief Executive Officer of EDAP TMS, added, "We are extremely pleased and excited Dr. Inderbir Gill has joined our U.S. clinical trial team to lead the team of investigators and support them actively in the current patient recruitment phase. His leadership and highly respected clinical reputation is key in the success of the enrollment program and therefore in finalizing, in the targeted timeframe, our HIFU clinical trial, heading to the Ablatherm HIFU FDA approval."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS SA

CONTACT:  EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com

Go to www.mysmartrend.com now for a FREE two-week trial.

Write to Chip Brian at cbrian@tradethetrend.com

---------------------------------------------------------------------------------------------

SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.TradeTheTrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.TradeTheTrend.com/signup.html

After the live Webcast, the call will remain available on EDAP's Website, www.edap-tms.com, through December 17, 2009. In addition, a telephonic replay of the call will be available until November 24, 2009. The replay dial-in numbers are (877) 660-6853 for domestic callers and (201) 612-7415 for international callers. Please use account number 356 and event ID number 337006.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com, http://www.hifu-planet.com and http://www.pcaresearch.com.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS SA

CONTACT:   EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com

In a press release out on November 4, IntegraMed(R) Announces New Enhanced Consumer Finance Solution for Fertility Treatments

PURCHASE, N.Y., Nov 04, 2009 -- IntegraMed America, Inc. (NASDAQ: INMD), the nation's leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced that it has partnered with Springstone Financial LLC to provide IntegraMed Fertility Network patients with improved financing options to fund Attain IVF Programs and certain other fertility treatments. Financing programs will be available to IntegraMed Fertility Network patients starting later this month.

About IntegraMed America, Inc.

IntegraMed America, Inc. manages highly specialized outpatient facilities in emerging, technology-based, niche medical markets and is the leading manager of fertility centers and vein clinics in the United States. IntegraMed supports its provider networks with clinical and business information systems, marketing and sales, facilities and operations management, finance and accounting, human resources, legal, risk management and quality assurance services. IntegraMed also offers treatment-financing programs for self-pay patients.

EDAP TMS SA (Nasdaq:EDAP) trading at $3.19 per share on trading volume of 44,725 shares.

In a press release out on November 4, EDAP Announces Webcast and Conference Call of Third Quarter 2009 Results

LYON, France, Nov 4, 2009 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today details relating to its third quarter 2009 earnings announcement, which will take place on Tuesday, November 17, 2009, before the opening of the market.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com,http://www.hifu-planet.com and http://www.pcaresearch.com.

ICOP Digital, Inc. (Nasdaq:ICOP) trading at $0.546 on a volume of 90,938 shares

In a press release out on November 4, ICOP to Host Teleconference on November 11, 2009

Management to Review Third Quarter 2009 Financial Results

LENEXA, Kan., Nov 4, 2009 -- ICOP Digital, Inc. (Nasdaq:ICOP), an industry-leading company engaged in advancing digital surveillance technology solutions, announced today that the Company will host a teleconference on November 11, 2009, to review its third quarter 2009 financial information and results. The Company plans to file its 10-Q on Friday November 13, 2009. ICOP is a leading provider of advanced digital video surveillance and management solutions.

About ICOP Digital, Inc.

ICOP Digital, Inc. (Nasdaq:ICOP) is a leading provider of mobile video solutions for Law Enforcement, Fire, EMS, Military, and Transportation markets, worldwide. ICOP solutions help the public and private sectors mitigate risks, reduce losses, and improve security through the live streaming, capture and secure management of high quality video and audio. www.ICOP.com

Celadon Group Inc. (NASDAQ: CLDN) trading at $9.51 on a volume of 33,055 shares

In a press release out on November 4, Celadon Group Announces Dates for Earnings Release and Conference Call

INDIANAPOLIS, Nov 04, 2009 -- Celadon Group Inc. (NASDAQ: CLDN) will release its fiscal 2010 second quarter results on Monday, January 25 after the close of the market. A conference call to discuss the quarter will be held on Tuesday, January 26 at 10:00 a.m. ET.

Celadon Group Inc. (www.celadongroup.com), through its subsidiaries, primarily provides long-haul, full-truckload freight service across the United States, Canada and Mexico. The company also owns Celadon Logistics Services, which provides freight brokerage; Celadon Dedicated Services, which provides supply chain management solutions, such as warehousing and dedicated fleet services; and TruckersB2B (www.truckersb2b.com) which provides cost savings to member fleets.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com email: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.